NCT06039696 Pathogenic Metagenomic Next-generation Sequencing to Optimize the Diagnosis of Decompensated Cirrhosis Infection
| NCT ID | NCT06039696 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Condition | Cirrhosis, Liver |
| Study Type | OBSERVATIONAL |
| Enrollment | 850 participants |
| Start Date | 2021-02-10 |
| Primary Completion | 2024-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 850 participants in total. It began in 2021-02-10 with a primary completion date of 2024-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about clinical application of pathogenic metagenomic next-generation sequencing to optimize the diagnosis of infection in decompensated cirrhotic patients. The main questions it aims to answer are: 1. mNGS testing in optimizing anti-infective drug use in patients with acute decompensation, including response to empiric antibiotic therapy. 2. Proportion of patients with re-compensation. 3. The positive rate of mNGS in patients with acute decompensated cirrhosis and the characteristics of pathogen. 4. The incidence, risk factors and clinical correlation of CMV reactivation.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old. * Diagnosis of cirrhosis, previously known or not, of any etiology, histologically proven or not. * Acute decompensation: ascites, digestive hemorrhage or hepatic encephalopathy. Exclusion Criteria: * Age \> 80 years old. * Malignancy of liver or other organs (including leukemia). * Receiving immunosuppressive agents for non-hepatic diseases. * HIV infection.
Contact & Investigator
Chen Jinjun
PRINCIPAL INVESTIGATOR
Nanfang Hospital, Southern Medical University
Frequently Asked Questions
Who can join the NCT06039696 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Cirrhosis, Liver. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06039696 currently recruiting?
Yes, NCT06039696 is actively recruiting participants. Contact the research team at chjj@smu.edu.cn for enrollment information.
Where is the NCT06039696 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06039696 clinical trial?
NCT06039696 is sponsored by Nanfang Hospital, Southern Medical University. The principal investigator is Chen Jinjun at Nanfang Hospital, Southern Medical University. The trial plans to enroll 850 participants.